ArticleIJU case reports2025
Long-Term Survival After Chemoradiotherapy for Renal Pelvis Cancer.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite the recent increase in applicable chemotherapy regimens for renal pelvic and ureteral cancer, patients with metastases still exhibit a poor prognosis. Here, we report a patient with renal pelvic cancer for whom long-term survival was achieved using chemoradiotherapy. Case Presentation: A 62-year-old woman diagnosed with renal pelvic cancer showed indications of a right renal pelvic tumor with para-aortic and iliac lymph node metastasis on computed tomography. Radiotherapy doses of 55 and 66 Gy were administered to the primary lesion, para-aortic lymph node, and right iliac lymph nodes after chemotherapy with gemcitabine, cisplatin, and docetaxel. Five years after treatment, no recurrence was observed. Conclusion: Chemoradiotherapy is a potential therapeutic option for patients with renal pelvic carcinoma in whom surgical intervention is challenging owing to complications or older age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.